John Tilton - Biohaven Pharmaceutical Chief Commercial Officer, Rare and Orphan Diseases
| BHVN Stock | USD 37.18 0.64 1.75% |
Executive
Mr. John Tilton is a Chief Commercial Officer, Rare and Orphan Diseases of Biohaven Pharmaceutical Holding Company Limited. Mr. Tilton has served as our chief commercial officer, rare and orphan diseases since April 2019 and, prior to that, as our chief commercial officer since April 2016. Prior to this, from November 2006 to March 2016, he served in increasingly senior marketing and business roles with Alexion Pharmaceuticals, Inc., including serving as its executive director, global sales and marketing operations from January 2011 to March 2016. Prior to his time at Alexion Pharmaceuticals, Mr. Tilton served as a director, division operations at Pfizer from August 2005 to November 2006, as a regional sales manager for Agouron Pharmaceuticals from November 1999 to August 2005 and as division manager at Sanofi from 1993 to 1999 since 2019.
| Age | 57 |
| Tenure | 6 years |
| Phone | 203 404 0410 |
| Web | https://www.biohaven.com |
Biohaven Pharmaceutical Management Efficiency
The company has return on total asset (ROA) of (1.1879) % which means that it has lost $1.1879 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.6545) %, meaning that it created substantial loss on money invested by shareholders. Biohaven Pharmaceutical's management efficiency ratios could be used to measure how well Biohaven Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Kendra Adams | C4 Therapeutics | N/A | |
| Scott Harris | Terns Pharmaceuticals | N/A | |
| Robert MD | Immunome | 64 | |
| Courtney Solberg | C4 Therapeutics | N/A | |
| Jeffrey Jensen | Inhibrx | N/A | |
| Kinney Horn | Immunome | 50 | |
| Pamela Danagher | Terns Pharmaceuticals | N/A | |
| Mayra ReyesArmour | C4 Therapeutics | N/A | |
| James Burns | Agios Pharm | 47 | |
| Ashraf Amanullah | Inhibrx | 57 | |
| Steven Vickers | Agios Pharm | N/A | |
| Christina Rossi | Blueprint Medicines Corp | 47 | |
| Robert Arbeit | X4 Pharmaceuticals | 77 | |
| Jolie JD | C4 Therapeutics | 48 | |
| Julian Baker | Blueprint Medicines Corp | 58 | |
| Soojin Kim | Inozyme Pharma | N/A | |
| Adam Dubow | Day One Biopharmaceuticals | 57 | |
| Max Rosett | Immunome | 35 | |
| FASCP MD | Inozyme Pharma | 70 | |
| Roee Shahar | Immunome | N/A | |
| Michael CPA | Blueprint Medicines Corp | 53 | |
Management Performance
| Return On Equity | -2.65 | ||||
| Return On Asset | -1.19 |
Biohaven Pharmaceutical Leadership Team
Elected by the shareholders, the Biohaven Pharmaceutical's board of directors comprises two types of representatives: Biohaven Pharmaceutical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Biohaven. The board's role is to monitor Biohaven Pharmaceutical's management team and ensure that shareholders' interests are well served. Biohaven Pharmaceutical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Biohaven Pharmaceutical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Warren JD, General Officer | ||
| John Childs, Independent Director | ||
| John Tilton, Chief Commercial Officer, Rare and Orphan Diseases | ||
| Rajesh Kumar, Senior Chain | ||
| Robert Hugin, Independent Director | ||
| Warren Volles, G Officer | ||
| Chris Barrett, Common Strategy | ||
| Michael Heffernan, Lead Independent Director | ||
| Vlad Coric, Chairman of the Board, Chief Executive Officer | ||
| Jennifer Porcelli, Vice Relations | ||
| Kishen Mehta, Director | ||
| Declan Doogan, Independent Chairman of the Board | ||
| Megan Dow, Vice Strategy | ||
| Steven Dworetzky, Senior Development | ||
| Dr DACVP, Chief Officer | ||
| Elyse Stock, Chief Medical Officer | ||
| Julia Gregory, Independent Director | ||
| Thomas Lynch, Chairman of the Board | ||
| Deb Young, Director Operations | ||
| Marianne MA, Senior Affairs | ||
| Gregory Bailey, Independent Director | ||
| Vladimir MD, Chairman CEO | ||
| George Clark, VP Officer | ||
| Matthew Buten, Chief Financial Officer | ||
| Gilbert Litalien, Senior Epidemiology | ||
| James Engelhart, Chief Financial Officer, Treasurer | ||
| Charles Conway, Chief Scientific Officer | ||
| Kimberly Gentile, Senior Vice President - Clinical Operations | ||
| George CPA, VP Officer | ||
| Robert Berman, Lead - Special Projects and Medical Oversight | ||
| Clifford MS, Chief Officer | ||
| William Jones, Chief Commercial Officer, Migraine and Common Diseases |
Biohaven Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Biohaven Pharmaceutical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -2.65 | ||||
| Return On Asset | -1.19 | ||||
| Current Valuation | 3.35 B | ||||
| Shares Outstanding | 101.12 M | ||||
| Shares Owned By Insiders | 11.70 % | ||||
| Shares Owned By Institutions | 92.56 % | ||||
| Number Of Shares Shorted | 8.62 M | ||||
| Price To Earning | (4.25) X | ||||
| Price To Book | 11.69 X | ||||
| EBITDA | (429.14 M) |
Pair Trading with Biohaven Pharmaceutical
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Biohaven Pharmaceutical position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Biohaven Pharmaceutical will appreciate offsetting losses from the drop in the long position's value.Moving against Biohaven Stock
The ability to find closely correlated positions to Biohaven Pharmaceutical could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Biohaven Pharmaceutical when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Biohaven Pharmaceutical - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Biohaven Pharmaceutical Holding to buy it.
The correlation of Biohaven Pharmaceutical is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Biohaven Pharmaceutical moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Biohaven Pharmaceutical moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Biohaven Pharmaceutical can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biohaven Pharmaceutical Holding. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biohaven Pharmaceutical. If investors know Biohaven will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biohaven Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Biohaven Pharmaceutical is measured differently than its book value, which is the value of Biohaven that is recorded on the company's balance sheet. Investors also form their own opinion of Biohaven Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Biohaven Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biohaven Pharmaceutical's market value can be influenced by many factors that don't directly affect Biohaven Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biohaven Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biohaven Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biohaven Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.